Main Article Content

Sonny T Lisal
Andi Jayalangkara Tanra
Burhanuddin Bahar
Erlyn Limoa
Andi Tenri Esa
Saidah Syamsuddin


Schizophrenia,, Vocational Therapy, Cognitive Function, IL-17, Risperidone


Background – Schizophrenia is a severe mental disorder in which chronic inflammation is one of the causes. Schizophrenia can affect the cognitive function of sufferers, therefore the management must be comprehensive by combining pharmacological and non-pharmacological therapies. Risperidone therapy combined with vocational therapy was thought could improve cognitive function in schizophrenic patients and was associated with changes in IL-17 levels.  Aim – To determine the effect of vocational therapy in improving cognitive function and IL-17 levels in schizophrenic patients receiving risperidone.


Method – Pre and post-test experimental analysis with non-random group selection. The number of subjects were 28 schizophrenic patients who were evenly divided into 2 groups, namely the treatment group receiving risperidone 2-6 mg/day with 8 weeks vocational therapy and the control group receiving only 2-6 mg risperidone/day. MoCA-Ina was cold to measure the cognitive function and the levels of IL-17. Comparison and correlation tests were performed between groups. 


Results – Vocational therapy had an effect on improving cognitive function in both groups (p 0.000). However, in the treatment group who received a combination of risperidone 2-6 mg/day and 8 weeks of vocational therapy had a better result.

Conclusion – Vocational therapy for 8 weeks with by risperidone therapy 2-6 mg/day could improve cognitive function in schizophrenic patients. Vocational therapy for 8 weeks did not affect IL-17 levels. There is no correlation between the improvement of cognitive function in schizophrenic object with changes in IL-17 levels experienced.

Abstract 89 | Pdf Downloads 68


[1] Chien W. T., Leung S. F., Yeung F. K., Wong W. K., “Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care,” Neuropsychiatric disease and treatment, vol. 9, pp. 1463, 2013.
[2] McDonald C., Murray R. M., “Early and late environmental risk factors for schizophrenia,” Brain Research Reviews, vol. 31, no. 2-3, pp. 130-137, 2000.
[3] Harrison P. J., Weinberger D. R., “Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence,” Molecular psychiatry, vol. 10, no. 1, pp. 40-68, 2005.
[4] Fan X., Go D. C., Henderson D. C., “Inflammation and Schizophrenia,” Expert Rev Neurother, vol. 7, pp. 789–96, 2007.
[5] Khandaker G. M., Dantzer R., Jones P. B., “Immunopsychiatry: important facts,” Psychological medicine, vol. 47, no. 13, pp. 2229-2237, 2017.
[6] Van Kesteren C. F. M. G., Gremmels H., De Witte L. D., Hol E. M., Van Gool A. R., Falkai P. G., Sommer I. E. C., “Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies,” Translational psychiatry, vol. 7, no. 3, pp. e1075-e1075, 2017.
[7] Meyer U., Schwarz M. J., Müller N., “Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond,” Pharmacology & therapeutics, vol. 132, no. 1, pp. 96-110, 2011.
[8] Kusumawardhani A.A.A.A., "Konsensus Penatalaksanaan Gangguan Skizofrenia", Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia, 2011.
[9] Ventriglio A., Ricci F., Magnifico G., Chumakov E., Torales J., Watson C., Bellomo A., “Psychosocial interventions in schizophrenia: Focus on guidelines,” International Journal of Social Psychiatry, vol. 66, no. 8, pp. 735-747, 2020.
[10] Mueser K. T., Becker D. R., Torrey W. C., Xie H., Bond G. R., Drake R. E., Dain B. J., “Work and nonvocational domains of functioning in persons with severe mental illness: A longitudinal analysis,” The Journal of nervous and mental disease, vol.185, no. 7, pp. 419-426, 1997.
[11] Sohn B. K., Hwang J. Y., Park S. M., Choi J. S., Lee J. Y., Lee J. Y., Jung H. Y., “Developing a virtual reality-based vocational rehabilitation training program for patients with schizophrenia,” Cyberpsychology, Behavior, and Social Networking, vol. 19, no. 11, pp. 686-691, 2016.
[12] Lexén A., Hofgren C., Stenmark R., Bejerholm U., “Cognitive functioning and employment among people with schizophrenia in vocational rehabilitation,” Work, vol. 54, no. 3, pp. 735-744, 2016.
[13] Pujam N. K., Nizamie S. H., Jayaswal M., “The Effect of Vocational Rehabilitation on Neurocognitive Function in Patients with Chronic Schizophrenia: A Prospective Study,” International Journal of Enhanced Research in Educational Development, vol. 4, pp. 20-25, 2016
[14] Frydecka D., Misiak B., Pawlak-Adamska E., Karabon L., Tomkiewicz A., Sedlaczek P., Beszłej J. A., “Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation, European archives of psychiatry and clinical neuroscience, vol. 265, no. 6, pp. 449-459, 2015.
[15] Xiu M. H., Man L. J., Wang D., Du X., Yin G., Zhang Y., Zhang X. Y., “Tumor necrosis factor‐alpha− 1031T/C polymorphism is associated with cognitive deficits in chronic schizophrenia patients versus healthy controls,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 177, no. 4, pp. 379-387, 2018.
[16] Wang J., Xu H., Wang D., Wei G., Zhou H., Wang L., Zhang X., “The interactive effect of genetic polymorphisms of IL-10 and COMT on cognitive function in schizophrenia,” Journal of Psychiatric Research, vol. 136, pp. 501-507, 2021.
[17] Barkić J., Filaković P., Radanović-Grgurić L., Koić O., Laufer D., Požgain I., Hotujac L., “The influence of risperidone on cognitive functions in schizophrenia,” Collegium antropologicum, vol. 27, no. 1, pp. 111-118, 2003.
[18] Reale M., Patruno A., De Lutiis M. A., Pesce M., Felaco M., Di Giannantonio M., Grilli A., “Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls,” BMC neuroscience, vol. 12, no. 1, pp. 1-9, 2011.
[19] Xiu M. H., Yang G. G., Tan Y. L., Tan S. P., Wang Z. R., De Yang F., Zhang X. Y., “Decreased interleukin-10 serum levels in first-episode drug-naïve schizophrenia: relationship to psychopathology,” Schizophrenia research, vol. 156, no. 1, pp. 9-14, 2014.
[20] Borovcanin M., Jovanovic I., Radosavljevic G., Dejanovic S. D., Bankovic D., Arsenijevic N., Lukic M. L., “Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse,” Journal of psychiatric research, vol. 46, no. 11, pp. 1421-1426, 2012.
[21] Dimitrov D. H., Lee S., Yantis J., Valdez C., Paredes R. M., Braida N., Walss-Bass C., “Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway,” Schizophrenia research, vol. 151, no. 1-3, pp. 29-35, 2013.
[22] Borovcanin M. M., Minic Janicijevic S., Jovanovic I. P., Gajovic N. M., Jurisevic M. M., Arsenijevic N. N., “Type 17 immune response facilitates progression of inflammation and correlates with cognition in stable schizophrenia,” Diagnostics, vol. 10, no. 11, pp. 926, 2020.

Most read articles by the same author(s)